Patent Extension “Wild Card” In Hatch/Lieberman Bill Depends On Five Factors
Executive Summary
Under a draft "BioShield II" bill from Sens. Orrin Hatch (R-Utah) and Joe Lieberman (D-Conn.), the length of a "wild card" patent extension would be partially dependent on the availability of alternatives to the bioterrorism countermeasure
You may also be interested in...
Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing
Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug
Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing
Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug
Hatch/Lieberman “BioShield II” Sets 180-Day Window For “Wild Card” Patents
Manufacturers who enter into biodefense contracts must notify the government within 180 days which patent would be covered by a potential "wild card" extension under the final version of "BioShield II" legislation from Sens. Orrin Hatch (R-Utah), Joe Lieberman (D-Conn.) and Sam Brownback (R-Kan.)
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: